



Neurocrine Biosciences to Present at Credit Suisse First Boston Health Care Conference

November 13, 2002

SAN DIEGO, Nov. 13 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will be presenting at the Credit Suisse First Boston Health Care Conference in Phoenix, Arizona at the Arizona Biltmore on Thursday, November 14, 2002 at 2:00PM Eastern Standard Time; 12:00PM Mountain Time; and 11:00AM Pacific Standard Time. The presentation will be simultaneously webcast and can be accessed on the Company's website only at the time specified above at <http://www.neurocrine.com> . A replay will be available approximately 24 hours after the live webcast.

Gary Lyons, President and CEO of Neurocrine will present the Company's clinical development program for indiplon for the treatment of insomnia and will also provide an update on the Company's broad development pipeline and research programs. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary audio software. If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 658-7600 and ask for Claudia Jones or Elizabeth Foster. The presentation will be archived until Monday, December 2, 2002.

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, malignant brain tumors and peripheral cancers, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, stroke, and certain female health disorders.

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at <http://www.neurocrine.com> .

Make Your Opinion Count - Click Here

<http://tbutton.prnewswire.com/prn/11690X34615822>

SOURCE Neurocrine Biosciences, Inc.